Trevena Inc. says its Phase III APOLLO pain studies for the new opioid Olinvo (oliceridine) will impress prescribers and payers, though the market clearly is skeptical about whether the data are good enough to secure competitive labeling and favorable positioning on formularies.
Oliceridine (TRV130) is an intravenous opioid analgesic that has been positioned as a safer, more effective choice over morphine and the drug has a breakthrough therapy designation from the US FDA